EXTON, PA — ProRx Pharma said it expanded its operations, tripled production capacity, and entered new markets to meet growing demand for compounded medications.
The company said it increased its facility size from about 3,400 square feet to approximately 17,000 square feet, adding clean rooms and specialized production areas for sterile and non-sterile drugs.
ProRx said the expansion has driven higher monthly production since December, with additional increases expected.
“We’ve tripled production capacity in a relatively short period of time,” Chief Operating Officer Kurt Lunkwitz said, adding that the company focused on scaling infrastructure while maintaining quality.
The company said it also expanded distribution into Oklahoma and Virginia, with plans to enter additional states.
ProRx has invested in automation, including an AI-based visual inspection system and aseptic filling equipment, to support production and quality control, according to the company.
The company said staffing has approximately doubled, with new hires across pharmacy, quality control, operations, and corporate roles.
ProRx said it plans to expand its product portfolio with new injectable medications, including testosterone and estradiol cypionate.
The company operates as an FDA-registered 503B outsourcing facility supplying compounded medications to healthcare providers nationwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.